Abstract: The present invention relates to an improved process for the preparation of amorphous (1S)-1,5-anhydro-1-[3-[[5 -(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-D-glucitol compound of formula-1, represented by the following structural formula.

Abstract: The present invention relates to an improved process for the preparation of amorphous (1S)-1,5-anhydro-1-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-D-glucitol compound of formula-1, represented by the following structural formula:

Abstract: An dabigatran etexilate intermediate of Formula-6a, and the use in the preparation of dabigatran etexilate thereof.

Abstract: An dabigatran etexilate intermediate of Formula-6a, and the use in the preparation of dabigatran etexilate thereof.

Abstract: The present invention relates to improved processes for the preparation of endolthelin receptor antagonists darusentan and ambrisentan, their salts and intermediates. Processes for the preparation of darusentan and ambrisentan comprise reacting benzophenone with a compound of Formula-3 to provide a compound of Formula-4, which on in-situ treatment with methanol and a suitable acid provides a compound of Formula-5; hydrolyzing the compound of Formula-5 to provide a compound of Formula-6; resolving the compound of Formula-6 to provide a compound of Formula-7; esterifying the compound of Formula-7 to provide a compound of Formula-8; reacting the compound of Formula-8 with a compound of Formula-9 to provide a compound of Formula-10; hydrolyzing the compound of Formula-10 to provide darusentan or ambrisentan; and purifiying darusentan or ambrisentan to provide darusentan or ambrisentan having purity greater than 99.00% by HPLC.

Abstract: The present invention relates to improved processes for the preparation of Endothelin receptor antagonists, their salts and intermediates.

Abstract: A crystalline Form II of 17?-N-[2,5-bis (trifluoromethyl)phenyl]carbamoyl-4-aza-5-?-androst-1-en-3-one (dutasteride) is provided. The preferred crystalline Form II of dutasteride has an X-ray powder diffraction pattern, expressed in terms of d-spacing (in ° A), with peaks at about 13.42, 6.96, 6.13, 5.27, 4.77, 4.70, 4.58, 4.46 and 3.82. A process for preparation of a crystalline Form II of dutasteride is also provided and includes dissolving a crude form of dutasteride in an alcoholic solvent having from 1 to 5 carbon atoms; removing the alcoholic solvent to obtain a residue; adding an ester solvent to the residue; and filtering the resulting separated solids. The processes of the invention are believed to be simple, eco-friendly, and commercially viable.

Abstract: The present invention relates to novel crystalline forms of atorvastatin calcium and to the methods of their production and isolation. More specifically, the present invention relates to novel Forms VI and VII of R—(R*, R*)]-2(4-fluorophenyl)-B, d dihydroxy-5(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1-H-pyrrole-1-heptanoic-acid calcium salt and hydrates thereof and to methods of their preparation.

Abstract: A crystalline Form II of 17&bgr;-N-[2,5-bis (trifluoromethyl)phenyl]carbamoyl-4-aza-5-&agr;-androst-1-en-3-one (dutasteride) is provided. The preferred crystalline Form II of dutasteride has an X-ray powder diffraction pattern, expressed in terms of d-spacing (in ° A), with peaks at about 13.42, 6.96, 6.13, 5.27, 4.77, 4.70, 4.58, 4.46 and 3.82. A process for preparation of a crystalline Form II of dutasteride is also provided and includes dissolving a crude form of dutasteride in an alcoholic solvent having from 1 to 5 carbon atoms; removing the alcoholic solvent to obtain a residue; adding an ester solvent to the residue; and filtering the resulting separated solids. The processes of the invention are believed to be simple, eco-friendly, and commercially viable.